CO34 | Inappropriate use of antibiotics in end-of-life patients: a single center retrospective study
Abstract
Premises and Purpose of the study: A 2023 report by WHO and ECDC has shown antimicrobial resistance as a threat to patients’(Pts) safety. The appropriate use of antibiotics in all healthcare settings is one of the tools to combat antibiotic resistance. Real-world data reporting antibiotic therapy (ATB) use in end-of-life Pts is limited.
Materials and Methods: A single-center observational retrospective cohort study was designed to investigate the antibiotic use of all end-of-life Pts admitted to the Internal Medicine Department of a tertiary care teaching Hospital in Northern Italy. Evaluated parameters: ATB in the last 72 and 24 hours of life, ATB under sedation, discontinuation of ATB, treatment variation, culture tests, empiric and targeted ATB.
Results: Between April and October ‘21, expected death occurred in 78 Pts (10.5% of all admitted Pts), 44 M, 33 F, median age 82.8 yrs (49-97), with an average hospitalization of 13.7 days. Palliative sedation was administered to 44 Pts (56%); the average duration was 21.8 hours. Urine and blood cultures were performed in 60% of Pts and 81% received empiric ATB. In 17% of cases ATB was changed from empiric to target in the last 72 hours. ATB was not interrupted in the last 72 hours in 56 Pts (71.8%) and in the last 24 hours in 44 Pts (56.4%); for 22 Pts (40%), antibiotics were administered until death.
Conclusions: Our study highlights the inappropriate use of antibiotics in end-of-life Pts with expected death. Improved knowledge of multidisciplinary end-of-life management should be encouraged within an antibiotic stewardship program.
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2025 the Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.